More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
The repeated failure of Roche’s ipatasertib increases the risk for Astrazeneca’s rival Akt inhibitor capivasertib.